Mitoxantrone Accord Healthcare (Mitoxantrone)

Mitoxantrone intercalates into DNA and stabilises the DNA‑topoisomerase II complex, preventing the re‑ligation of DNA strands during replication. This creates double‑strand breaks, halts DNA synthesis, and triggers apoptosis in rapidly dividing cancer cells.

The dosing schedule for Mitoxantrone is determined by the prescribing oncologist based on the specific cancer type, patient weight, renal and hepatic function, and treatment protocol. Only a qualified healthcare provider can set the appropriate dose and frequency.

The safety of Mitoxantrone in pregnancy and lactation has not been established. It is generally contraindicated in pregnant or nursing women because of potential fetal toxicity and the risk of drug transfer through breast milk. Consultation with a specialist is essential.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where needed) and import documentation.

Mitoxantrone shares a similar DNA‑intercalating mechanism with other anthracenediones but differs in its pharmacokinetic profile and toxicity spectrum. Compared with agents like doxorubicin, Mitoxantrone may have a lower incidence of acute cardiotoxicity but still requires cardiac monitoring and carries a risk of secondary leukaemia.

Mitoxantrone Accord Healthcare should be stored at 2‑8 °C in a refrigerator. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the solution to maintain stability.

Mitoxantrone is supplied as an intravenous solution and must be administered by a qualified healthcare professional. The infusion is typically given over a prescribed period, often diluted in a compatible IV fluid, and monitored for infusion‑related reactions.

The most serious risks include cardiotoxicity (reduced heart function), secondary acute myeloid leukaemia or myelodysplastic syndrome, severe myelosuppression leading to infections or bleeding, and hepatic or renal failure. Patients should be closely monitored for these events throughout treatment.

Patients with known hypersensitivity to Mitoxantrone or other anthracenediones, those with uncontrolled cardiac disease, severe hepatic or renal impairment, or active uncontrolled infections should generally avoid Mitoxantrone. The prescribing physician will assess suitability on an individual basis.